Bárbara Bruni

Dr. Bárbara Bruni

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BBBárbara Bruni
Bárbara Bruni
IAIsraa Mohamad Alakhras Aljnadi
Israa Mohamad Alakhras Aljnadi
RERita Emídio
Rita Emídio
EMEduarda Mendes
Eduarda Mendes
APAlexandra Paulo
Alexandra Paulo
Cancer is a societal burden demanding innovative approaches. A major problem with the conventional chemotherapeutic agents is their strong toxicity and other side effects due to their poor selectivity. Uncontrolled proliferation of cancer cells is due to mutations, deletions, or amplifications in genes (oncogenes) encoding for proteins that regulate cell growth and division, such as transcription factors, for example, c-MYC. The direct targeting of the c-MYC protein has been attempted but so far unsuccessfully, as it lacks a definite binding site for the modulators. Meanwhile, another approach has been explored since the discovery that G-quadruplex secondary DNA structures formed in the guanine-rich sequences of the c-MYC promoter region can downregulate the transcription of this oncogene. Here, we will overview the major achievements made in the last decades towards the discovery of a new class of anticancer drugs targeting G-quadruplexes in the c-MYC promoter of cancer cells.

27 March 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
IAIsraa Mohamad Alakhras Aljnadi
Israa Mohamad Alakhras Aljnadi
BBBárbara Bruni
Bárbara Bruni
RERita Emídio
Rita Emídio
SMSiona Manocha
Siona Manocha
MTMalak Tousson
Malak Tousson
APAlexandra Paulo
Alexandra Paulo
The quadruplex DNA structures formed by the guanine-rich sequences (G4) present in promoter regions of oncogenes, like c-MYC, are emerging as selective anticancer drug targets, with two molecules in phase I clinical trials. G4s are dynamic structures regulating several genome processes and being regulated by helicases. Moreover, not only oncogene promoter G4s are increased in cancer cells, but also helicases are overexpressed in these cells, thus making these two genome regulators attractive targets for anticancer intervention. Herein we disclose the structure of a new small molecule with high affinity and selectivity to the cMYCG4 (Kb = 6.7 ± 0.6 x 10^6 M^-1 or KD= 0.15 ± 0.01 µM), capacity to inhibit the activity of the helicase DHX36 with Ki ~ 7 µM and antiproliferative activity in breast cancer cells overexpressing c-MYC, with IC50 values also in the low µM range. Importantly, due to the reduced number of protonable groups, this new inhibitor of DHX36-mediated G4-unfolding activity is a better drug lead molecule than the previously reported ones. The mechanism of action of this compound in breast cancer cells is now being investigated.